Evolus Shares Decline Following Major Equity Grants to New Executives

Evolus Inc. shares experienced a notable decline of 4.26% during Friday’s trading session, closing at $7.19. This downward movement coincided with the company’s disclosure of substantial equity compensation packages awarded to several newly appointed executives, with the Chief Financial Officer receiving the most significant allocation.

The board’s compensation committee approved these grants for seven new hires. Tatjana Mitchell, who joined the company as CFO on September 8, received the largest package, which included:

• 143,403 stock options with an exercise price of $7.61 per share
• 104,603 restricted stock units (RSUs)
• A four-year vesting schedule with annual increments

Six other recently hired employees received combined compensation of 8,744 stock options priced at $7.66 along with 15,000 RSUs. All stock options feature a ten-year expiration term.

Should investors sell immediately? Or is it worth buying Evolus?

Trading volume reached 707,868 shares on the day of the announcement and subsequent price decline. The stock’s recent performance demonstrates its ongoing volatility, with closing prices fluctuating from $7.61 on September 8 (which established the reference price for the CFO’s options) to $7.51 on September 11, before settling at Friday’s $7.19 close.

The significant equity dilution resulting from these substantial compensation packages raises questions about their potential impact on existing shareholders and the company’s long-term value creation strategy.